Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease.
A well-established model of bowel inflammation is the HLA-B27 transgenic rat that exhibits a spontaneous disease phenotype resulting in chronic diarrhea caused by immune cell activation. Estrogens have previously been shown to modulate the immune system, and both estrogen receptors (ERalpha and ERbeta) are present in the intestine and cells of the immune system. Therefore, the ability of estrogen to ameliorate disease progression in the HLA-B27 transgenic rat was determined. HLA-B27 transgenic rats with chronic diarrhea were treated with 17alpha-ethynyl-17beta-estradiol (EE) for 5 days. EE treatment dramatically improved stool scores after only 3 days. Histological scores of the degree of ulceration, inflammatory cell infiltration, fibrosis, and lesion depth of the colon were also improved by EE treatment. Because neutrophil infiltration into the colon is involved in the development and propagation of disease, myeloperoxidase (MPO) activity was measured. MPO levels were reduced by 80% by EE treatment. Cotreatment with the pure ER antagonist ICI-182780 (ICI) blocked the effects of EE on stool character, MPO activity, and histology scores, strongly suggesting that the activity of EE is mediated through ER. Mast cell proteases can promote neutrophil infiltration, and gene expression analysis demonstrated that mast cell protease 1, 3, and 4 mRNA were all decreased in colons from estrogen-treated rats. In addition, a direct effect of estrogen on bone marrow-derived mast cell activity was demonstrated, suggesting that ER-mediated inactivation of mast cells may contribute to the improvement in the clinical sign and histological scores in this model.
Harnish
Douglas C
DC
Cardiovascular and Metabolic Disease Research, Wyeth, Collegeville, PA 19426, USA. Harnisd@wyeth.com
Albert
Leo M
LM
Leathurby
Yelena
Y
Eckert
Amy M
AM
Ciarletta
Agnes
A
Kasaian
Marion
M
Keith
James C
JC
D000818:Animals; D030801:Animals, Genetically Modified; D001854:Bone Marrow Cells / Q000187:drug effects / Q000502:physiology; D015550:Cell Degranulation / Q000187:drug effects; D003106:Colon / Q000201:enzymology / Q000473:pathology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D010450:Endopeptidases / Q000096:biosynthesis / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000077267:Fulvestrant; D015796:HLA-B27 Antigen / Q000235:genetics*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008407:Mast Cells / Q000187:drug effects / Q000502:physiology; D016328:NF-kappa B / Q000502:physiology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism
D016207:Cytokines; D015796:HLA-B27 Antigen; D016328:NF-kappa B; D011960:Receptors, Estrogen; D000077267:Fulvestrant; D004958:Estradiol; D009195:Peroxidase; D001619:beta-N-Acetylhexosaminidases; D010450:Endopeptidases